We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Diabetes

Journal Scan / Research · March 14, 2021

RCT of Anti–interleukin-21 for β-Cell Function in Adult, Recent-Onset Type 1 Diabetes

The Lancet Diabetes & Endocrinology

 

Additional Info

The Lancet Diabetes & Endocrinology
Anti–Interleukin-21 Antibody and Liraglutide for the Preservation of β-Cell Function in Adults With Recent-Onset Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
Lancet Diabetes Endocrinol 2021 Mar 01;[EPub Ahead of Print], M von Herrath, SC Bain, B Bode, JO Clausen, K Coppieters, L Gaysina, J Gumprecht, TK Hansen, C Mathieu, C Morales, O Mosenzon, S Segel, G Tsoukas, TR Pieber

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading